Cordis (medical)
![]() | This article contains content that is written like an advertisement. (December 2017) |
![]() | |
Founded | 1957 (as The Medical Development Corporation) |
---|---|
Founder | Dr. William P. Murphy Jr. |
Headquarters | Santa Clara, California, U.S. |
Area served | Worldwide |
Products | Medical devices |
Website | Cordis.com |
Cordis develops and manufactures medical devices for diagnostics and interventional procedures to treat patients with coronary and peripheral vascular diseases.
Cordis was founded in 1959 in Miami, Florida, and currently operates in North America, Europe, the Middle East, Africa, Asia-Pacific, and Latin America markets. The Cordis global headquarters are jointly located in Baar, Switzerland, and Santa Clara, California. The headquarters also acts as a hub for Cordis' operations in Europe, Africa, and the Middle East. The North American operations are based out of the San Francisco Bay area. The Asia-Pacific hub is located in Singapore, and the Latin American hub is in Puerto Rico.[1]
History
The Medical Development Corporation was founded in 1957 in Miami, Florida, by Dr. William P. Murphy Jr. and focused on interventional vascular medicine and neuroscience.[1] In 1959, the company's name changed to Cordis.[1]
In 1962, the first synchronous cardiac pacemaker co-developed by Cordis was implanted in a patient.[2] During the 1970s, Cordis introduced the first sheath introducers with hemostasis valves, designed to minimize blood loss during an angioplasty procedure.[citation needed] In the 1980s, Cordis launched a line of percutaneous transluminal coronary angioplasty (PTCA) guiding catheters.[citation needed]
In the 1990s, Cordis introduced the first PTCA balloon utilizing nylon balloon material.[citation needed] In 1994, Cordis received FDA-approval for the first bare-metal stent in the US, the PALMAZ-SCHATZ Balloon-Expandable Stent for coronary artery applications.[3][4] In 1996, Cordis joined the Johnson & Johnson Intervention Systems (JJIS).[1][5][6] In 1997, Cordis Corporation expanded into electrophysiology after Johnson & Johnson acquired Biosense Inc. and merged it with Cordis.[7] In 1998, Biosense Inc. merged with Webster Laboratories to form Biosense Webster, Inc.[citation needed]
In 2002, the CYPHER Sirolimus-eluting Coronary Stent, the first drug-eluting stent for patients with coronary heart disease was approved for use in the EU.[8] In 2010, EXOSEAL a vascular closure device with extravascular bio absorbable plug placement received CE-mark in Europe.[9] In 2013, Cordis launched the Smart Flex Self-Expanding Stent System, a self-expanding vascular stent.[10] In 2014, Cordis Corporation announced the launch of its INCRAFT AAA Stent Graft System (INCRAFT System), a device for use during endovascular aneurysm repair (EVAR) for patients with infrarenal abdominal aortic aneurysms (AAA).[11][12]
In 2015, Cardinal Health acquired the Cordis business from Johnson & Johnson for $1.944 billion.[13][14]
On October 31, 2016, Cardinal Health announced several new strategic distribution agreements enabling Cordis, Cardinal Health's interventional vascular business, to expand its product portfolio. These distribution agreements were related to coronary stents and percutaneous transluminal coronary angioplasty (PTCA) balloon catheters in Cordis' portfolio of products that support the treatment of patients undergoing percutaneous coronary intervention.[15]
In 2017, Cordis received the CE Mark for its RAILWAY Sheathless Access System, which enables direct access to the radial artery with a guiding catheter and eliminates the need for an introducer sheath, reducing the size of the arterial puncture site.[16][17] On March 31, 2017, Cardinal Health announced two new strategic agreements that enabled Cordis, Cardinal Health's interventional vascular business, to expand its cardiology product offering in China. These strategic agreements added new percutaneous transluminal coronary angioplasty (PTCA) balloon catheters, manufactured both in China and internationally, to the Cordis' portfolio.[18]
In March 2021, Cardinal announced plans to sell Cordis to private equity firm Hellman & Friedman for $1 billion.[14]
Product categories
Cardiology products
- PTCA Balloons
- Guiding catheters
- Diagnostic catheters
- Diagnostic guidewires
- Steerable guidewires
- Catheter sheath introducers
- Sheathless access system
- Transradial products
- Vascular closure devices
- Emboli protection devices
- Biopsy forceps
Endovascular products
- Self-expanding stents
- Pre-mounted balloon expandable stents
- Unmounted balloon expandable stents
- PTA balloons
- Diagnostic catheters
- Guiding catheters
- CTO catheters
- Diagnostic guidewires
- Steerable guidewires
- Catheter sheath introducers
- Venous products
- Vascular closure devices
- Emboli protection devices
References
- ^ a b c "Gateway City/Who's Here: Cordis plant in Miami Lakes produces high-tech cardiac catheter components for world market". Miami Herald. 25 October 2015. Archived from the original on 2015-10-26.
- ^ Jeffrey, Kirk (2003-04-01). Machines in Our Hearts: The Cardiac Pacemaker, the Implantable Defibrillator, and American Health Care. JHU Press. ISBN 978-0-8018-7616-5.
- ^ Scott (2007-05-24). "J&J Returns to Old-School Stents". Wall Street Journal. ISSN 0099-9660. Retrieved 2021-08-26.
- ^ "FDA Approves New Heart Stents". Associated Press. 22 December 1997.
{{cite web}}
: CS1 maint: url-status (link) - ^ "COMPANY NEWS;JOHNSON & JOHNSON WILL COMPLETE PURCHASE OF CORDIS". The New York Times. 23 January 1996. ISSN 0362-4331. Retrieved 2021-08-26.
- ^ STIEGHORST, TOM. "CORDIS APPROVES J&J MERGER". Sun-Sentinel.com. Archived from the original on 2021-07-02. Retrieved 2021-08-26.
- ^ "Johnson & Johnson Buys Biosense For $400 Mln in Shares - Globes". en.globes.co.il (in Hebrew). 1997-09-29. Retrieved 2021-08-26.
- ^ "Cordis to Stop Making Cypher, Nevo Stents". www.medpagetoday.com. 2011-06-15. Retrieved 2021-08-26.
- ^ "Cordis's ExoSeal Receives CE Mark Approval". Endovascular Today. Archived from the original on 2021-08-26. Retrieved 2021-08-26.
- ^ "Medtronic, J&J's Cordis headline EuroPCR 2013". FierceBiotech. 21 May 2013. Retrieved 2021-08-26.
- ^ "Cordis brings Incraft AAA stent graft to Europe and Canada". MassDevice. Archived from the original on 2019-10-04. Retrieved 2021-08-26.
- ^ "Incraft low-profile endograft launched in Europe and Canada". Vascular News. 2014-09-09. Archived from the original on 2019-07-04. Retrieved 2021-08-26.
- ^ "J&J confirms $1.9B sale of Cordis unit to Cardinal Health, ending months of speculation". FierceBiotech. 2 March 2015. Retrieved 2021-08-26.
- ^ a b "Cardinal Health to sell off its Cordis device division in $1B deal". FierceBiotech. 15 March 2021. Retrieved 2021-08-26.
- ^ "Cardiac Interventions Today - Cardinal Health Announces Strategic Distribution Agreements in International Markets". Cardiac Interventions Today. Retrieved 2017-06-22.
- ^ "Cordis Railway Sheathless Access System Approved in Europe". Cardiac Interventions Today. Retrieved 2021-08-26.
- ^ "Cordis Unveil New Interventional Cardiology Products | Medgadget". Retrieved 2021-08-26.
- ^ "Top Global Medical Device Companies - Medical Product Outsourcing". www.mpo-mag.com. Retrieved 2021-08-26.
- CS1 maint: url-status
- CS1 Hebrew-language sources (he)
- Articles with short description
- Articles with a promotional tone from December 2017
- All articles with a promotional tone
- All articles with unsourced statements
- Articles with unsourced statements from August 2021
- AC with 0 elements
- Johnson & Johnson subsidiaries
- Medical technology companies of the United States
- Companies based in Fremont, California